Background: Several cross-sectional studies have reported that thyroid hormone levels are associated with cardiovascular risk markers and metabolic syndrome (MetS) even in euthyroid subjects. However, the prognostic role of serum thyroid hormone levels in the risk of incident MetS has not been elucidated. Aim: We aimed to investigate the associations of baseline serum thyroid hormone levels with the development of MetS in healthy subjects. Methods: This 6-year, cross-sectional, longitudinal and follow-up study was conducted in 12 037 euthyroid middleaged subjects without MetS subjected to comprehensive health examinations. Subjects were grouped according to total triiodothyronine (T3) quartiles. The hazard ratio (HR) for the development of MetS according to T3 quartiles was estimated using Cox proportional hazards model. Results: During the 6-year period, 3544 incident cases of MetS (29%) were identified. The proportion of subjects with incident MetS increased across the T3 quartiles (P for trend <0.001). The HR and 95% confidence interval (CI) for the development of MetS were significantly higher in the highest T3 quartile compared with the lowest T3 quartile even after adjusting for confounding variables including gender, age and smoking (HR: 1.238, 95% CI: 1.128-1.358, P < 0.001). Conclusion: In euthyroid middle-aged subjects, serum T3 levels are associated with increased risk for future development of MetS.
Introduction
Metabolic syndrome (MetS) is a complex disease characterized by several abnormalities including central obesity, glucose intolerance, hypertension and dyslipidemia (1, 2) . MetS is considered the disease with the fastest growing incidence (3) and is the most important disease worldwide because of the increased risk of cardiovascular morbidity and mortality (4, 5) . To establish a better therapeutic and preventive strategy for MetS, a better understanding of its mechanisms is necessary.
Thyroid disease is associated with atherosclerotic cardiovascular disease (6, 7) . In addition, thyroid hormones have been reported to influence energy homeostasis (8) , lipid and glucose metabolism (9, 10, 11) and blood pressure (BP) (12) . Therefore, the study of the association between serum thyroid hormone levels and components of MetS is essential.
Recently, several cross-sectional studies have reported that thyroid hormone levels are associated with MetS even in euthyroid subjects (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25) . Serum thyroid-stimulating hormone (TSH) levels within the reference range have been positively associated with components of MetS (19, 20, 21, 22, 23, 24) . Low normal free thyroxine (fT4) levels have been associated with MetS parameters (13, 14, 15, 16, 17, 18) , whereas high normal total triiodothyronine (T3) or free triiodothyronine (fT3) levels have been positively correlated with components of MetS (14, 18, 25) . However, the prognostic role of serum thyroid hormone levels in the risk of incident MetS was not assessed in those crosssectional studies.
Herein, we aimed to investigate the associations of baseline serum thyroid hormone levels with the development of MetS in a large population of euthyroid subjects.
Subjects and methods

Study population
Middle-aged subjects between 35 and 65 years were tested by a comprehensive clinical examination, which is every once per year, at least more than four consecutive times within six years (between January 2006 and December 2012; n = 22 955) at the Health Promotion Center of Samsung Medical Center (Fig. 1 ). Among these subjects, 10 918 were excluded for the following reasons, on the basis of the 2006 records: known cardiovascular disease including coronary heart disease and/or stroke (n = 567), subjects met the criteria for MetS (n = 3546), absence of data (questionnaire, anthropometric measurements, HbA1c, insulin, TSH, T3 and/or T4; n = 7531), abnormal thyroid function (TSH, T3, and/or T4 below or above the normal reference range; n = 1992), abnormal liver function (aspartate aminotransferase and/or alanine aminotransferase ≥2.5 above the upper limit of normal; n = 101) and/or abnormal kidney function (serum creatinine levels >1.3 mg/dL; n = 75)). Several subjects met more than two criteria. After exclusion of ineligible participants, 12 037 subjects (6950 men and 5087 women with a mean age of 50.2 years) were deemed eligible and were included in the study. All data on anthropometric variables, laboratory tests, radiologic images and coded answers to self-report questionnaires were stored in an electronic medical record. Informed consent requirement for this study was waived by the institutional review board because researchers only accessed the database for analysis purposes, and personal identifying information was not accessed. The study protocol was approved by the Institutional Review Board at Samsung Medical Center.
Definitions of euthyroidism
Euthyroidism was defined as serum TSH (reference range: 0.4-5.0 U/L), T3 (reference range: 76-190 ng/dL) and T4 (reference range: 4.7-12.5 µg/dL) levels within their normal reference range.
Definitions of metabolic syndrome
Considering a joint interim statement of the International Diabetes Federation (IDF), the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) criteria (26) , American College of Endocrinology position statement (27) and our modifications, MetS was defined when three or more of the following criteria were met: (1) fasting glucose levels ≥100 mg/dL or participants were on antidiabetic treatment; (2) BMI ≥25 kg/m 2 ; (3) triglycerides (TG) levels ≥150 mg/dL; (4) high-density lipoprotein (HDL) cholesterol levels <40 mg/dL in men and <50 mg/dL in Figure 1 Flow chart of the study population.
women and (5) BP ≥130/85 mmHg or participants were on antihypertensive treatment.
Clinical and laboratory measurements
The smoking status was assessed using a questionnaire completed during an interview and was classified as never smoker, former smoker or current smoker. Height and weight were measured while subjects were wearing light clothing without shoes. BMI was calculated as weight in kilograms divided by height in meters squared (kg/m 2 ). Percentage body fat and waistto-hip ratio were estimated using a multi-frequency bioimpedance analyzer (InBody 720, Biospace Co., Seoul, Korea) with eight-point tactile electrodes (2 electrodes for each foot and hand) and were validated for reproducibility and accuracy for body composition (28) . BP was measured using an automatic manometer with the participants in a seated position after a 5-min resting period. After overnight fasting, blood samples were collected from the antecubital vein into vacuum tubes and subsequently analyzed at a central, certified laboratory at Samsung Medical Center. Total cholesterol, low-density lipoprotein (LDL) cholesterol, HDL cholesterol and TG levels were measured with an enzymatic colorimetric method using a Modular D2400 analyzer (Roche Diagnostics). Blood glucose concentration was measured using a nonenzymatic method. HbA1c level was measured using an immunoturbidimetric assay with a Cobas Integra 800 automatic analyzer (Roche Diagnostics) and a reference value range of 4.4-6.4%. HbA1c measurements were standardized with a reference method by following the standards of the Diabetes Control and Complications Trial (DCCT) and the National Glycohemoglobin Standardization Program (NGSP). Serum insulin concentration was measured using an immunoradiometric assay (TFB Co., Ltd, Tokyo, Japan). As a marker of insulin resistance, the homeostatic model assessment of insulin resistance (HOMA-IR) was calculated using the following formula: HOMA-IR = (fasting insulin (μIU/mL) × fasting glucose (mmol/L))/22.5 (29) . Serum TSH levels were measured using an immunoradiometric assay kit (Immunotech, Marseille Cedex, France). Serum T3 and T4 levels were measured using a radioimmunoassay kit (FT4 RIA KIT; Immunotech).
Study design and statistical analysis
All 12 037 subjects were divided into two groups according to whether or not they developed MetS during a mean follow-up period of 65.9 months. In addition, all subjects were categorized into quartiles on the basis of their TSH and T3 levels using following reference ranges: (1) two-sided, and analyses were executed using SPSS for windows, version 14.0. A P value of less than 0.05 was considered statistically significant.
Results
The baseline clinical and biochemical characteristics of 12 037 subjects, including those who developed MetS during a 6-year period, are summarized in Table 1 . Of these, 6950 subjects (58%) were men, with a mean age of 50.2 ± 7.1 years at baseline. The serum TSH and T3 levels were 2.3 ± 1.3 U/L and 111.4 ± 18.3 ng/dL respectively. During the 6-year period, 3544 incident cases of MetS (29%) were identified. Among them, 2701 (76%) were men. The characteristics of the subjects with respect to the development of MetS are presented in Table 1 . Subjects who subsequently developed MetS were more likely to be older and current or former smokers. They also had higher baseline values of BMI, body fat percentage, waist-to-hip ratio, systolic BP, diastolic BP, total cholesterol, LDL cholesterol, TG, fasting glucose, HOMA-IR and T3, but lower level of HDL cholesterol and TSH compared with those who did not develop MetS. There was no significant difference in T4 levels between the two groups. We further explored clinical and biochemical characteristics at baseline according to TSH quartiles (Supplementary Table 1 , see section on supplementary data given at the end of this article) and T3 quartiles ( Table 2) . As the TSH quartile increased, the proportion of men decreased, and subjects were more likely to be never smokers. Positive associations between TSH quartiles and total cholesterol were observed, whereas negative associations were observed between TSH quartiles and BMI, diastolic BP, fasting glucose and T4 levels. There were no significant differences between TSH quartiles and age, body fat percentage according to gender, waist-to-hip ratio according to gender, systolic BP, LDL cholesterol, HDL cholesterol according to gender, TG and T3. As the T3 quartile increased, the proportion of men increased, and subjects were more likely to be older and current or former smokers. Positive associations between T3 quartiles and BMI, body fat percentage, waist-to-hip ratio, systolic BP, diastolic BP, total cholesterol, LDL cholesterol, HDL cholesterol, TG, fasting glucose, HbA1c, HOMA-IR and T4 were observed. There were no significant differences between T3 quartiles and the levels of TSH.
The proportion of subjects with incident MetS decreased across the TSH quartiles (Supplementary Table 2 , P for trend <0.001). The HR of incident MetS significantly decreased as the TSH quartile increased. However, no associations were observed after additional adjustment for confounding variables including gender, age and smoking. Table 3 Hazard ratio (HR) and 95% confidence intervals (CI) for the development of metabolic syndrome among 12 037 euthyroid subjects based on triiodothyronine quartiles during a 6-year period. HR and 95% CI for development of metabolic syndrome were estimated using Cox proportional hazard regression analysis. All P values and 95% CI for HR were corrected by Bonferroni's method due to multiple testing. 
Figure 2
Kaplan-Meier plots showing a cumulative incidence of metabolic syndrome according to triiodothyronine quartiles during the follow-up period (P < 0.001 using the log-rank test).
The proportion of subjects with incident MetS increased across the T3 quartiles (Table 3 , P for trend <0.001). Kaplan-Meier analysis showed a mean event period for MetS of 70.8 (95% CI: 69.9-71.7), 69.6 (68.7-70.5), 67.6 (66.6-68.6) and 65.4 (64.4-66.4) months for subjects belonging to Q1, Q2, Q3 and Q4 respectively (Fig. 2, P < 0.001 using the log-rank test) . In a Cox proportional hazard model (Table 3) , the HR of incident MetS significantly increased as the T3 quartile increased. Additional adjustment for confounding variables such as gender, age and smoking attenuated those effects. However, the highest T3 quartile continued to be a significant risk factor for developing MetS even after such adjustments (HR: 1.238, 95% CI: 1.128-1.358, P < 0.001).
Discussion
To the best of our knowledge, this is the first longitudinal observational study reporting an association between thyroid hormone levels and incident MetS in a healthy population. At baseline, subjects who subsequently developed MetS had unfavorable metabolic profiles and high T3 levels, compared with those who did not develop MetS. Higher T3 levels were strongly associated with unfavorable metabolic profile and increased risk of incident MetS in euthyroid middle-aged subjects during the 6-year period. In addition, we found an independently positive association between T3 levels and incident MetS even after adjusting for gender, age and smoking. On the other hand, we found no associations between serum TSH levels within reference range and risk of incident MetS despite the significant correlation between TSH levels and several metabolic parameters.
Recent cross-sectional studies have reported that T3 or fT3 levels were associated with various metabolic parameters in euthyroid individuals (14, 18, 25, 30, 31, 32, 33) . T3 and/or fT3 levels had positive associations with body composition variables including BMI (14, 18, 25, 31, 32, 33) , waist circumference (14, 18, 31, 32) , waist-tohip ratio (18, 31) , subcutaneous fat layer (31) and whole body and trunk fat mass (25, 33) . We also observed strong positive associations between higher T3 levels and body fat parameters including BMI, body fat percentage and waist-to-hip ratio. Moreover, subjects who subsequently developed MetS had higher baseline T3 levels compared with those who did not develop MetS. Although the exact mechanisms underlying the association between thyroid hormones and unfavorable body composition or obesity are not clear, several mechanisms have been suggested. First, previous studies have suggested that leptin predominantly released by adipocytes could be a mediator. In the hypothalamus, leptin stimulates TRH gene expression directly in the paraventricular nucleus (34, 35) and indirectly in the arcuate nucleus (34) . In humans, leptin-stimulated TRH release increases circulating T3 and T4 concentrations, but not TSH concentrations (36) . In mice, the thyroid gland expresses the long form of leptin receptors, and the administration of leptin to euthyroid animals increases circulating concentrations of T3 and T4 without affecting circulating concentrations of TSH (37, 38) . Second, it has been suggested that changes in the activity of iodothyronine deiodinase lead to the conversion of T4 to T3. In addition, changes in type I deiodinase activity in white adipose tissue under the conditions of changing adiposity and the stimulatory effects of leptin on this activity were demonstrated in mice (39) . Increases in type I deiodinase mRNA levels and enzyme activity in adipose tissue were documented in obese humans (40) . However, no studies have reported changes in type II deiodinase activity in humans with increased adiposity. Third, a moderate increase in T3 and fT3 levels within the upper normal range in obesity may be regarded as an adaptation process for increased energy expenditure in response to increased body weight. Fasting and overfeeding studies on the role of thyroid hormones in the weight status showed that serum T3 concentrations decreased during fasting (41) and increased during overfeeding (42) . In addition, T3 concentrations decreased after reducing overweight (43, 44, 45) .
Increase in cardiac output affects tissue oxygen consumption, blood volume, cardiac contractility and heart rate, which are mechanisms that may link T3 to BP (6) . The administration of T3 has been shown to induce hypertension and myocardial hypertrophy in rats (46) . Moreover, T3 is known to stimulate the activity of reninangiotensin systems (47, 48) . Roef et al. (18) demonstrated that higher T3 and fT3 levels were associated with higher systolic and diastolic BP. Bakker et al. (49) revealed that serum fT3 levels in healthy euthyroid subjects correlated positively with systolic and diastolic BP, independent of age and gender. Therefore, our results on the positive association between T3 and systolic and diastolic BP in euthyroid subjects are consistent with those of previous studies (18, 25, 49) .
In the present study, subjects who subsequently developed MetS had higher baseline total cholesterol, LDL cholesterol and TG, but lower HDL cholesterol compared with those who did not develop MetS. On the other hand, positive associations between T3 quartiles and total cholesterol, LDL cholesterol, HDL cholesterol and TG were observed. Generally, the effects of thyroid hormones on lipid metabolism include enhanced utilization of lipid substrates, increased synthesis and mobilization of TG stored in adipose tissue, increased concentration of non-esterified fatty acids and increased lipoprotein-lipase activity (50) . These findings are in contrast with our result on the relationship between T3 levels and lipid profiles. It is assumed that the association between T3 levels and lipid profiles is affected by gender, age, smoking status, body composition and insulin resistance.
Insulin resistance appears to be important to the pathophysiology of MetS (51) and has been reported to be associated with hyperthyroidism (52) . In addition, it has been postulated that insulin sensitivity is regulated by thyroid hormones. The glucose transporter 2 and glucokinase play an important role as glucose sensors in pancreatic beta-cells (53) and the expression of glucose transporter 2 and glucokinase mRNA and protein can be modulated by T3 in pancreatic islets (54) . In the context, the administration of T3 to healthy subjects resulted in insulin resistance (55) . In addition, it has been reported that T3 may play a role in the regulation of insulin secretion, and in vitro studies using human and rat insulinoma cell lines showed that T3 promoted cell proliferation and protected cells from apoptosis in islet β-cell lines (56) . Treatment of a human pancreatic duct cell line with T3-induced morphological and functional changes as indicated by a marked increase in insulin synthesis, transdifferentiation of this cell line into insulin-producing β-cells and upregulation of insulin and glucose transporter 2 mRNA levels (57). Ortega et al. (30) showed that fT3 levels were associated with insulin secretion independent of insulin sensitivity and glucose concentration in euthyroid individuals. In this study, we observed that higher T3 levels at baseline were associated with lower insulin sensitivity assessed by HOMA-IR and with higher fasting glucose levels in healthy euthyroid subjects. Our results are in agreement with those of Roef et al. (33) who noted that serum T3 and fT3 levels were positively associated with insulin and HOMA-IR levels. Lambadiari et al. also found a significant positive relationship of HOMA-IR and fT3 levels with early stages of type 2 diabetes after adjusting for age, gender and BMI in euthyroid subjects (52) . Very recently, Roef et al. (18) showed that T3 and fT3 levels were positively associated with fasting glucose levels.
Therefore, strong associations have been found between T3 levels and several elements of MetS in healthy euthyroid subjects. The hazard ratio for MetS increased from the lowest to the highest quartiles of T3 even after adjusting for confounders. It is well known that the prevalence of MetS is higher in men than that in women (51) and the prevalence of thyroid dysfunction is higher in women than that in men (58) . The prevalence of MetS increases with each decade of life and in parallel with the age-related increase in obesity (51) . In addition, smoking is associated with both thyroid function and body composition. Because subjects who develop MetS in this study were predominantly men, older and current or former smokers, we adjusted for potential confounders including gender, age and smoking.
Some cross-sectional studies showed a positive relation between TSH levels within the reference range and prevalent MetS (23, 59) , whereas others found no association (21) . Conversely, we found that the proportion of subjects with incident MetS decreased across the TSH quartiles. Although HR of incident MetS significantly decreased as the TSH quartile increased, no associations were observed after additional adjustment for confounding variables including gender, age and smoking. The inconsistent results between TSH levels within the reference range and MetS may be due to differences in study populations, in the categorization of thyroid function, in the factors included for adjustments in the analyses and in cross-sectional or longitudinal approaches.
Few studies have evaluated the association between fT4 or T4 within the reference range and MetS or its parameters, and inverse associations between fT4 levels within reference range and metabolic parameters have been found (13, 16, 18, 21, 31) . Among these studies, two cross-sectional studies investigated the association of free T4 levels with MetS, and discordant results were found between studies. One study found an association between low normal fT4 levels and MetS (21), whereas another study did not (16) . For T4, two studies identified positive associations between T4 levels within the reference range and metabolic profiles (25, 33) . In the current study, data on fT4 levels were not available in most subjects, so we focused on T4 rather than fT4. Positive associations between T3 quartiles and T4 levels were observed.
The main limitation of our study is its retrospective nature. We did not measure anti-TPO antibodies to exclude potential underlying chronic autoimmune thyroid disease and disregarded information on other exposures, including alcohol intake and physical activity, which influence metabolic profiles. In addition, data on waist circumference in the assessment of obesity were not available. However, the availability of other anthropometric data, including BMI, percentage of body fat and waist-to-hip ratio, may overcome this limitation.
To date, no longitudinal study has evaluated the association between T3 levels and the development of MetS. A strength of our study involved analysis of data from 12 037 consecutive subjects and the assessment of the development of MetS among euthyroid subjects during a 6-year period.
In conclusion, higher T3 levels were associated with increased risk of developing MetS in euthyroid middle-aged subjects. Further research on the potential mechanisms underlying the relationship between thyroid hormones and metabolic profiles may provide insights into the etiology of the MetS and help establish better therapeutic and preventive strategies.
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